Use of bismuth subgallate in inhibition of production of nitric oxide synthase

Abstract

The present invention discloses the new use of bismuth subgallate for use in the inhibition of the production of nitric oxide synthase. Also disclosed is the synergistic efficacy of bismuth subgallate in combination with borneol in the inhibition of the production of nitric oxide synthase.

What is claimed is:  
     
         1 . A method of inhibiting the production of nitric oxide synthases (NOS) in a subject, comprising administering to said subject in need thereof bismuth subgallate in an amount effective to inhibit the production of NOS.  
     
     
         2 . The method of  claim 1 , further comprising administering to said subject in need thereof borneol in an amount synergistically effective to inhibit the production of NOS.  
     
     
         3 . A pharmaceutical composition for use in the inhibition of the production of NOS, which comprises a bismuth subgallate for use in the inhibition of the production of NOS in an effective amount sufficient to inhibit the production of NOS and a pharmaceutical acceptable carrier.  
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the amount of bismuth subgallate ranges from 0.05 to 40 percent by weight.  
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the amount of bismuth subgallate ranges from 1 to 20 percent by weight.  
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein the amount of bismuth subgallate ranges from 2 to 10 percent by weight.  
     
     
         7 . The pharmaceutical composition of  claim 3  further comprising borneol, wherein the amounts of bismuth subgallate and borneol are synergistically effective for inhibiting the production of NOS.  
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the amount of bismuth subgallate and that of borneol range from 1 to 30 percent by weight and from 0.05 to 10 percent by weight, respectively.  
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the amount of bismuth subgallate and that of borneol range from 3 to 15 percent by weight and from 0. 1 to 5 percent by weight, respectively.  
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the amount of bismuth subgallate and that of borneol range from 4 to 8 percent by weight and from 0.5 to 1 percent by weight, respectively  
     
     
         11 . The pharmaceutical composition of  claim 3 , which further comprises another NOS inhibitor.  
     
     
         12 . The pharmaceutical composition of  claim 7 , which further comprises another NOS inhibitor.  
     
     
         13 . The pharmaceutical composition of  claim 3 , which is administered in topical, oral or parenteral route.  
     
     
         14 . The pharmaceutical composition of  claim 7 , which is administered in topical, oral or parenteral route.  
     
     
         15 . A method of treating diseases in a subject in which nitric oxide production is implicated, comprising administering to said subject in need thereof an effective amount of bismuth subgallate.  
     
     
         16 . The method of  claim 15 , further comprising administering to said subject in need thereof a borneol in an amount synergistically effective to inhibit the production of NOS.  
     
     
         17 . The method of  claim 15 , wherein the diseases are selected from the group consisting of: platelet aggregation deficiency, homeostatic process disorder, tissue injury, migraine, inflammatory diseases, stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, AIDS associated dementia, neurodegenerative diseases, neuron toxicity, Alzheimer's disease, chemical dependencies and addictions, emesis, epilepsy, anxiety, psychosis, head trauma, adult respiratory distress syndrome (ARDS), morphine induced tolerance and withdrawal symptoms, inflammatory bowel disease, osteoarthritis, rheumatoid arthritis ovulation, dilated cardiomyopathy, acute spinal cord injury, Huntington's disease, Parkinson's disease, glaucoma, macular degeneration, diabetic neuropathy, diabetic ulcers and cancer in a mammal.  
     
     
         18 . The method of  claim 15 , wherein the disease is platelet aggregation deficiency.  
     
     
         19 . The method of  claim 15 , wherein the disease is homeostatic process disorder.  
     
     
         20 . The method of  claim 18 , wherein the treatment of homeostatic process disorders has an effect on rapid hemostasis.  
     
     
         21 . The method of  claim 15 , wherein the disease is tissue injury.  
     
     
         22 . The method of  claim 15 , wherein the disease is inflammatory disease.  
     
     
         23 . The method of  claim 22 , wherein the inflammatory disease is asthma.  
     
     
         24 . The method of  claim 15 , wherein the disease is a diabetic ulcer.